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ABSTRACT
Objective To evaluate the clinical accuracy of the
IONA® test for aneuploidy screening.
Methods This was a multicenter blinded study in which
plasma samples from pregnant women at increased risk
of trisomy 21 underwent cell-free DNA analysis utilizing
the IONA test. For each sample, the IONA software
generated a likelihood ratio and a maternal age-adjusted
probability risk score for trisomies 21, 18 and 13.
All results from the IONA test were compared against
accepted diagnostic karyotyping.
Results A total of 442 maternal samples were obtained,
of which 437 had test results available for analysis and
assessment of clinical accuracy. The IONA test had a
detection rate of 100% for trisomies 21 (n = 43; 95% CI,
87.98–100%), 18 (n = 10; 95% CI, 58.72–100%) and
13 (n = 5; 95% CI, 35.88–100%) with cut-offs applied
to likelihood ratio (cut-off > 1 considered high risk
for trisomy) and probability risk score incorporating
adjustment for maternal age (cut-off ≥ 1/150 considered
high risk for trisomy). The false-positive rate (FPR) was
0% for trisomies 18 and 13 with both analysis outputs.
For trisomy 21, a FPR of 0.3% was observed for the
likelihood ratio, but became 0% with adjustment for
maternal age.
Conclusion This study indicates that the IONA test is
suitable for trisomy screening in a high-risk screening
population. The result-interpretation feature of the
IONA software should facilitate wider implementation,
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particularly in local laboratories, and should be a useful
addition to the current screening methods for trisomies 21,
18 and 13. © 2015 The Authors. Ultrasound in Obstetrics
& Gynecology published by John Wiley & Sons Ltd
on behalf of the International Society of Ultrasound in
Obstetrics and Gynecology.
INTRODUCTION
Non-invasive prenatal testing (NIPT), using methods
of cell-free DNA (cfDNA) analysis, provides the most
accurate assessment for fetal trisomies 21, 18 and 13,
compared with screening methods that combine maternal
age, and ultrasound and serum biochemical markers. In a
recent meta-analysis, the weighted pooled detection rates
for trisomies 21, 18 and 13 in singleton pregnancies were
99.2%, 96.3% and 91.0%, for false-positive rates (FPRs)
of 0.09%, 0.13% and 0.13%, respectively1.
Recent NIPT technologies are based predominantly
on next-generation sequencing (NGS)2,3. This enables
rapid and effective clinical testing and commonly uses
either the Illumina (Illumina, Inc., San Diego, CA, USA)
or Thermo Fisher Scientific (Thermo Fisher Scientific,
Waltham, MA, USA) platforms. The key advantages of
an ion semiconductor sequencing platform (Ion Proton™,
Thermo Fisher Scientific) are the rapid sequencing speed
and fast turnaround time with low upfront capital and
operating costs. These are important considerations in
the context of screening for aneuploidy, particularly if
wider implementation is envisaged. The IONA® test
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd ORIGINAL PAPER
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(Premaitha Health plc, Manchester, UK) uses the Ion
Proton sequencing platform and has a turnaround time,
from the start of sample processing to a result, of 3 days.
It uses bioinformatics interpretation to determine the
relative number of chromosomal copies, which enables the
detection of a fetal aneuploidy. Published reviews indicate
that various technical issues have the potential to affect the
accuracy of sequences obtained by NGS, such as frequent
insertion and deletion errors and difficulties posed by
homopolymer tracts of identical bases4–8. The algorithms
developed for use in IONA software (Premaitha Health
plc) are designed to overcome such issues.
The main aim of this study was to investigate the
accuracy of the IONA test in the discrimination between
euploid pregnancies and those affected by fetal trisomies
21, 18 and 13.
METHODS
In this multicenter blinded study, the screening accuracy
of the IONA test by NGS was evaluated using plasma
samples obtained from pregnant women considered to be
at higher risk of fetal trisomy on conventional screening
and who underwent definitive karyotyping by invasive
testing. The likelihood ratio, age-adjusted probability
(risk) and sensitivity and specificity in the detection of
trisomies 21, 18 and 13 were calculated.
Study population and sample collection
The study was conducted using blood samples collected
from pregnant women under appropriate institutional
and ethical approval. Written informed consent was
obtained from all participants. Study participants were
recruited between April 2008 and November 2014
from six hospital centers in England. Eligible patients
were at least 18 years of age, with a singleton or twin
pregnancy of at least 10 weeks’ gestation and a clinical
indication for an invasive procedure (screen-positive
result from conventional aneuploidy screening such as the
combined test, quadruple test, fetal structural anomaly
on ultrasound examination or advanced maternal
age). Exclusion criteria included higher-order multiple
pregnancy (triplets or more), known mosaicism, partial
trisomy or translocations, fetal demise, disappearing
twin, malignancy or known aneuploidy in the pregnancy.
Peripheral maternal blood (20 mL) was collected into
standard ethylenediaminetetraacetic acid blood collection
tubes. Demographic information obtained at subject
recruitment included maternal age, height, weight and
gestational age. Data on pregnancy outcome in all
participants were obtained from each center. The results
of cfDNA testing were not made available to participants.
The study samples analyzed included all trisomy 21,
18 and 13 samples available that met the eligibility
criteria, plus unaffected samples that were selected to
reflect the prevalence of trisomy 21 observed during
sample collection in the high-risk population (i.e. 1:9). The
unaffected samples were selected using random sampling
techniques from all eligible samples.
Cell-free DNA preparation and sequencing
The procedural workflow for the IONA test was
divided into the following steps. Day 1: (1) plasma
separation and cfDNA extraction (3.5 h), (2) automated
library construction (8 h), and (3) automated emulsion
polymerase chain reaction (PCR) (library amplification
and enrichment; 13.5 h, running overnight). Day 2: (4)
Library DNA sequencing (5 h), and (5) automated data
analysis (3 h). This results in a processing time of 35 h
for up to 32 samples, in multiples of eight, for optimal
throughput.
Within 8 h of blood draw, the maternal blood samples
were centrifuged at 1600 g for 10 min and the plasma
fraction was removed and stored at −20 ◦C or below. On
receipt of the samples at the study laboratory they were
centrifuged for a further 10 min at 16 000 g to remove any
cellular material, before being frozen at −80 ◦C. Prior to
analysis, the plasma sample was defrosted and centrifuged
for 1 min at 3000 g. The resultant cfDNA was isolated,
extracted and sequenced from 1.0–2.5 mL of maternal
plasma, which contained both maternal and fetal cfDNA.
The cfDNA was extracted using an automated DNA
extraction platform (QIASymphony, Qiagen, Hilden,
Germany) and used for DNA library preparation using
the IONA Library Preparation Kit in combination with
an automated liquid handling platform (Sciclone, Perkin
Elmer, Inc., Waltham, MA, USA). The IONA run control
DNA library was included in order to ascertain the validity
of the sequencing run performed. The run control material
consisted of a DNA library of two cell lines combined
to give an input concentration of 10% trisomy 21.
Semiconductor whole-genome sequencing was performed
using Ion Chef™ and Ion Proton™ systems (Thermo Fisher
Scientific), according to the manufacturer’s instructions,
as a multiplex of eight samples in addition to the IONA
run control (four sequencing runs per day were performed
to achieve the 32-sample optimal throughput).
Sample processing and analysis were performed by
appropriately trained and experienced operators who
were blinded to karyotype results throughout the study.
The IONA test results were compared to the results from
invasive testing or birth outcome.
Data analysis
Overview of process
Sample information, including anonymized patient data,
was entered via the IONA software interface. A unique
sample identifier (‘test instance ID’) was allocated and
used to identify the passage of a sample through the
system, linked to demographic and patient data entered
previously. This was used to identify each sample against
its corresponding barcoded adapter in the sequencing
multiplex. The multiplex data were presented to the
IONA software, which executed the main bioinformatics
processing pipeline, generating the test report ‘run and
sample validity’ information.
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Data generation and bioinformatics processing
Execution of the main bioinformatics pipeline proceeded
as follows. For each sequencing run of eight samples,
multiplexed sequence reads were retrieved from the
sequencing platform in the form of an unmapped BAM
file. The multiplexed assembly of reads was initially sub-
ject to a barcode classification step, in which barcoded 5′
adapters were identified and matched against a predefined
set, in order to separate the multiplex into reads against
individual samples for further processing. Following an
early filtering step to remove a small number of very
short reads, fragments were mapped to the ‘hg19’ human
genome reference using a gap-tolerant read-alignment
module. Post-filtering of alignment results was then car-
ried out to remove duplicate reads arising in PCR stages
of the test workflow, determined as those whose 5′ end
mapped to the reference at the same position as any other
read. Fragments determined to have aligned uniquely
in the genome reference were then binned according to
autosome origin, with the resulting counts subject to
a calibration step to correct sequencing coverage bias
correlated to GC base pair content. Finally, the resulting
fragment count data were used as input to a set of mixture
models that incorporate distributions of expected values
under both trisomy-affected and -unaffected hypotheses
for trisomies 13, 18 and 21 tests. Each model generated
a test likelihood ratio that was then used, together with
maternal age-derived prior probability of trisomy, to
quantify the probability of each trisomy, taking into
account both age and the corresponding DNA test result.
In this way the IONA software interprets the results, so
the pipeline generates a final risk result without the need
for further local bioinformatics analysis.
The IONA software also performed internal validity
checks. Following the generation of per-autosome
fragment counts, the ‘run validity’ check took place. This
step first isolated fragments derived from sequencing the
run control, and then compared the proportion of counts
from these fragments that aligned against chromosome
21 using a reference range determined previously as part
of a specification-setting study. If the proportion met the
reference criteria, the ‘run validity’ check passed.
Separate validity checks were also performed for each
sample. These ensured that the aligned fragment count
was sufficient for the likelihood mixture model to be used,
and that the fraction of cfDNA in the sample that was fetal
in origin was sufficient for a result to be reported; fetal
fraction was quantified using a custom bioinformatics
method developed in-house.
Statistical analysis
Sensitivity and specificity values were reported based
on the predefined cut-offs for likelihood ratio and
probability. Point estimates have been provided together
with 95% CIs (Clopper–Pearson binomial proportions
method). For the purposes of the IONA test, a ‘trisomy test
result’ is considered to be ‘positive’ if the likelihood ratio
result is > 1; this threshold value follows implicitly from
the conventional statistical interpretation of a likelihood
ratio value. With regards to age-adjusted probability (risk)
of trisomy, a probability ≥ 1 in 150 was considered to
be a screen-positive (high-risk) result, as used in the UK
National Health Service (NHS)9.
RESULTS
In this study 442 samples were processed with the IONA
test; however, five of these did not meet the validity criteria
applied by the IONA software (two samples did not have
sufficient DNA fragment counts and three samples did
not contain sufficient fetal DNA) and were excluded from
subsequent analysis. Reports were generated by the IONA
software for all remaining 437 samples.
Median maternal age at testing was 35 (range, 18–
55) years and median gestational age was 15 + 3 (range,
11 + 0 to 36 + 4) weeks. Median maternal weight was
66 (range, 46.0–151.5) kg and median maternal height
was 165 (range, 152–189) cm.
Data from the reference method (amniocentesis,
chorionic villus sampling (CVS) or birth outcome) were
available for all 437 cases, and identified 43 fetuses with
trisomy 21 (one twin), 10 with trisomy 18 (one twin),
five with trisomy 13 and 379 that were unaffected by
trisomies 13, 18 or 21 (nine twins) (Figure 1).
Table 1 shows the summary of cfDNA analysis results
for the age-adjusted likelihood ratio probability model
for each trisomy screened for compared with the results
of the reference method (amniocentesis, CVS or birth
outcome). Table 2 shows the sensitivity (detection rate)
and specificity measures for the likelihood ratio model
and the maternal age-adjusted probability model. Plots of
the age-adjusted probability (risk score) distribution for
each trisomy are shown in Figures 2, 3 and 4, showing all
valid samples analyzed.
Normal
(n = 379)
T21 T18 T13
IONA test result
(≥ 1 in 150 cut-off for
low/high age-adjusted
risk probability)
n = 43 n = 10 n = 5 n = 379
n = 43 n = 10 n = 5 n = 379*
n = 0 n = 0 n = 0 n = 0
n = 0 n = 0 n = 0 n = 0
Total samples
(n = 437)
Chromosomal abnormality
(n = 58)
False negatives
False positives
Reference test result
Figure 1 Patient flow through the study showing results of the
reference test (amniocentesis, chorionic villus sampling or birth
outcome) and the IONA® test. *One sample was positive for
trisomy (T) 21 using just the likelihood ratio but was normal once
adjusted for age-related prior risk.
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Table 1 Likelihood ratio and maternal age-adjusted probability of
the IONA® test, tabulated against results of the reference method
(amniocentesis, chorionic villus sampling or birth outcome), for
detection of trisomies 21, 18 and 13 in 437 maternal serum
samples, using a probability risk cut-off of ≥ 1 in 150
Reference method
IONA test result Unaffected Trisomy Total
Likelihood ratio
Unaffected 378 0 378
Trisomy 21 1 43 44
Trisomy 18 0 10 10
Trisomy 13 0 5 5
Total 379 58 437
Age-adjusted probability
Unaffected 379 0 379
Trisomy 21 0 43 43
Trisomy 18 0 10 10
Trisomy 13 0 5 5
Total 379 58 437
Initial analysis, which produces the likelihood ratio,
detected one result for a trisomy 21 that was dis-
cordant with that of the reference method. However,
following adjustment for maternal age-related prior
risk, the probability risk score was concordant with the
reference-method result, at the UK screening cut-off of
≥ 1 in 150. Similar results were observed at low/high
risk cut-offs of 1 in 50 and 1 in 250. At a cut-off of 1 in
500, one false-positive case of trisomy 21 was observed,
demonstrating that the higher the cut-off used the more
likely a false-positive result will occur.
A detection rate of 100% was demonstrated for tri-
somies 21 (n = 43; 95% CI, 87.98–100%), 18 (n = 10;
95% CI 58.72 to 100%) and 13 (n = 5; 95% CI,
35.88–100%) for both analysis outputs. The speci-
ficity for the likelihood ratio calculations were 99.75%
(95% CI, 98.59–99.99%) for trisomy 21, 100% (95% CI,
98.71–100%) for trisomy 18 and 100% (95% CI,
98.72–100%) for trisomy 13, resulting in an FPR of
0.3%, 0% and 0%, respectively. Once the results were
adjusted to give the final age-adjusted probability (risk
score), the specificity was 100% (with respective 95% CI,
98.60–100%, 98.71–100% and 98.72–100%) with a
0% FPR for all three trisomies. The failure rate was 1.1%,
comprising low fetal fraction in 0.7% and low counts in
0.4%. There were no false positives or false negatives
for trisomies 21, 18 and 13 identified by the IONA test
0.20.0 0.4
Age-adjusted probability of trisomy
0.6 0.8 1.0
Figure 2 Maternal age-adjusted probability (risk score) for trisomy
21, computed at blood-draw date, in 437 maternal serum samples
that were tested using the IONA® test. , unaffected sample; ,
trisomy-21 sample; , cut-off (1 in 150).
when compared to the outcome by the reference method
of amniocentesis, CVS or birth outcome.
DISCUSSION
We have demonstrated that the screening performance of
the IONA test for the detection of trisomies 21, 18 and
13 is similar to that of other cfDNA screening techniques
for these common aneuploidies1.
The typical turnaround time for the IONA test is 3 days,
from plasma sample collection to report generation.
This short turnaround time may reduce the levels of
parental anxiety and allow decision-making in relation to
pregnancy options and management.
This study adds to a growing body of literature regard-
ing the use of semiconductor sequencing NGS in cfDNA
prenatal aneuploidy screening7,8. The key advantages of
this technology include lower upfront and operating costs
as well as a reduced turnaround time, which are impor-
tant considerations in the developing high-throughput
screening programs. Liao et al. recently described a
detection rate of more than 98% for trisomies 21, 18 and
13 using the Ion Proton semiconductor sequencer8, whilst
Table 2 Sensitivity and specificity of likelihood ratio and maternal age-adjusted probability of the IONA® test for detection of trisomies 21,
18 and 13 using amniocentesis, chorionic villus sampling or birth outcome as the reference method
Likelihood ratio>1 Maternal age-adjusted probability ≥ 1:150
Trisomy Sensitivity (% (95% CI))* Specificity (% (95% CI))* Sensitivity (% (95% CI))* Specificity (% (95% CI))*
Trisomy 21 100.00 (87.98–100.00) 99.75 (98.59–99.99) 100.00 (87.98–100.00) 100.00 (98.60–100.00)
Trisomy 18 100.00 (58.72–100.00) 100.00 (98.71–100.00) 100.00 (58.72–100.00) 100.00 (98.71–100.00)
Trisomy 13 100.00 (35.88–100.00) 100.00 (98.72–100.00) 100.00 (35.88–100.00) 100.00 (98.72–100.00)
*Any sample not affected by trisomy 21, 18 or 13 was considered unaffected.
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2016; 47: 188–193.
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Figure 3 Maternal age-adjusted probability (risk score) for trisomy
18, computed at blood-draw date, in 437 maternal serum samples
that were tested using the IONA® test. , unaffected sample; ,
trisomy-18 sample; , cut-off (1 in 150).
0.20.0 0.4
Age-adjusted probability of trisomy
0.6 0.8 1.0
Figure 4 Maternal age-adjusted probability (risk score) for trisomy
13, computed at blood-draw date, in 437 maternal serum samples
that were tested using the IONA® test. , unaffected sample; ,
trisomy-13 sample; , cut-off (1 in 150).
a feasibility study by Jeon et al. reported 100% positive
and negative predictive values for both trisomies 21 and
187. Our study extends the number of samples analyzed
using semiconductor sequencing and demonstrates that
when this approach is coupled with a defined work
flow and the error-tolerant algorithms incorporated in
the IONA software the result is an accurate cfDNA
methodology appropriate for trisomy screening.
In contrast to studies reported previously7,8, we report
likelihood ratio and age-adjusted screening results rather
than a simple Z-score. This approach has a number
of advantages: the likelihood ratio is computed from a
mixture model that takes into account distributions of
sequence-derived indicator values for both the unaffected
and trisomy-affected subpopulations. This value is,
therefore, more informative in the overall statistical
context of the test than a Z-score, which is generally
referenced only to a single assumed normal distribution
of unaffected sequence values. Additionally, the use
of a mixture model framework affords flexibility in
including additional factors derived from the sequencing
workflow, which improve the fit of the model to empirical
distributions by adapting to workflow conditions and
thereby improving the accuracy of the result.
Since the model operates in a similar statistical
framework to that of biomarker-based screening tests, the
likelihood ratio result is directly compatible with analysis
methods and models already well established in the
screening community. This then allows Bayesian statistical
methods to be employed to combine the cfDNA-specific
result with any prior information available on trisomy
risk, such as age-related risk or first-trimester combined
screening, in order to give a more accurate overall
patient-specific risk estimate10. Although a cut-off of
≥ 1/150 was applied for high/low risk as used by the
UK NHS9, other cut-offs can be applied using the IONA
software, to account for country or clinician preference.
Strengths and limitations of the study
In addition to the generation of a more patient-specific
risk estimate, other strengths of the study include the large
number of trisomy 21 samples, robust blinding to fetal
karyotype during sample processing and analysis, high
ascertainment of pregnancy outcome and the reporting
and break down of no-result (‘failure’) rate.
It could be argued that one of the main limitations of
this study is that all women recruited were at increased risk
of aneuploidy. However, it is recognized that the accuracy
of cfDNA analysis relies on the precision of the assay and
the fetal fraction rather than on prevalence of aneuploidy
in the study population11,12. As the reported performance
of NIPT in aneuploidy screening is similar between studies
reporting on high-risk and low-risk populations2,11,13–16,
we believe that the results of this study, in terms of the
screening performance of the IONA test, are also relevant
to a population at low risk of aneuploidy.
Although the IONA test predicted accurately the
aneuploidy status in the 11 twin pregnancies studied,
the overall number of twin pregnancies in this study was
small. The literature on NIPT in twin pregnancy remains
limited, with only six studies published so far17–22.
There is a need for further evaluation of NIPT in twins as
multiple pregnancies carry a higher risk of chromosomal
anomalies with a higher FPR when using existing screen-
ing tests for aneuploidy and therefore a greater likelihood
© 2015 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd Ultrasound Obstet Gynecol 2016; 47: 188–193.
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of being offered invasive testing with a higher risk of
procedure-related complications of invasive testing23,24.
The design of this study intentionally excluded any
known mosaicism or vanishing twin to enable direct
evaluation of screening performance of the IONA test
for detection of fetal aneuploidy and to make our study
comparable to similar published studies25–27. It would
be entirely appropriate to ensure future studies are on
unselected samples without such exclusions.
The IONA test does not screen for sex-chromosome
aneuploidy, a practice that remains controversial due to
ethical concerns, the mild phenotype in the majority of
cases, high reported failure rate, low positive predictive
value and high FPR, and the high rate of mosaicism in
affected pregnancies28–30.
In conclusion, this study demonstrates that the IONA
test can accurately predict the presence of trisomies
21, 18 and 13. We have demonstrated the principle of
using a similar statistical framework to biomarker-based
screening tests by reporting the likelihood ratio, which
allows the cfDNA-specific result to be combined with
prior information on trisomy risk, such as maternal age,
in order to give a patient-specific risk estimate. The IONA
test system provides a simple, relatively inexpensive,
complete CE-marked in-vitro diagnostic system for
trisomies 21, 18 and 13 that includes automated result
interpretation that facilitates implementation in local
laboratories. The relatively short turnaround time has
the potential to reduce the stress of prospective parents
awaiting results.
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